Articles

Find an Article

Filter articles

Showing 11 to 20 of 745 results

Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox

Japan27-05-2022Takanori Abe

Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.

Gene-editing bill: encouraging innovation or adding complexity?

UK26-05-2022Sarah Speight

UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.

Neurim, Flynn discover that time is not on their side

UK26-05-2022Lydia Birch

The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

South Africa: homeopathy case clarifies ‘medicine’ definition

South Africa23-05-2022Kareema Shaik and Jenny Pienaar

South Africa’s Supreme Court has declared regulations on complementary medicines invalid, explain Kareema Shaik and Jenny Pienaar of Adams & Adams.

Predicting the unpredictable during pregnancy

International19-04-2022Fran Salisbury and Alice Jefferies

A pressing need for more non-invasive prenatal tests is leading to increasing IP activity and commercial interest, say Fran Salisbury and Alice Jefferies of Mewburn Ellis.

Solving the PCT Priority problem

International14-04-2022Chiara Banas

The ‘joint applicants’ approach to PCT applications would provide an elegant solution to issues of who is entitled to priority claims in PCT applications, suggests Chiara Banas of EIP.

G 2/21: how to support inventive steps in patentability

EU07-04-2022Sarah Gibbs

A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.

The fall of COVID-19 and the rise of antimicrobial resistance

International17-03-2022Donald McNab and Mark Schuster

With evidence of antimicrobial resistance increasing, can innovation incentives drive pharma to fight back? Donald McNab and Mark Schuster of Marks & Clerk explore.

Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing

Japan08-03-2022Takanori Abe

Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.

SurgiSil: Lip implant case shows looks can be deceiving

US03-03-2022Elizabeth Ferrill

A seemingly small decision by the US Court of Appeals for the Federal Circuit could have a big impact on owners of design patents, explains Elizabeth Ferrill of Finnegan.

Showing 11 to 20 of 745 results

LSIPR